Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
There is a distinct lack of published literature on the effect of combination treatment of
PEG-interferon and ribavirin on post-renal transplantation hepatitis C virus (HCV) patients.
Small case series have been published utilizing conventional interferon and/or ribavirin and
the available data is extremely preliminary in nature. A small retrospective series of
patients treated with Pegylated interferon and ribavirin published recently suggests that the
treatment may be safe and efficacious. Unpublished reports from a few centers within Saudi
Arabia also suggest a good safety profile and reasonable efficacy from this form of
combination treatment.
The investigators aim to prospectively study the safety and efficacy of PEG-interferon and
ribavirin combination therapy in post-renal transplant HCV-infected patients. Towards this 40
patients with histological evidence of liver disease will be recruited and the efficacy of
the above medications studied.
The proposed study aims to evaluate the efficacy and safety of PEG-interferon and ribavirin
combination therapy in the treatment of chronic HCV in renal transplant patients in a way
that will allow management of such patients in an optimized manner.
Phase:
Phase 4
Details
Lead Sponsor:
King Abdulaziz Medical City
Collaborators:
King Faisal Specialist Hospital & Research Center Riyadh Military Hospital